Omeprazole Stada (Omeprazole)

Omeprazole Stada is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine disorder.

• Omeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By forming a covalent disulfide bond with the pump’s sulfhydryl groups, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduction of gastric acidity.

Adverse reactions to Omeprazole Stada may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: increased intestinal gas.
• Constipation: occasional bowel habit change.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis.
• Acute interstitial nephritis: kidney inflammation.
• Stevens‑Johnson syndrome: severe skin reaction.
• Hepatotoxicity: liver enzyme elevation.
• Hypomagnesemia: low magnesium levels.
• Fracture risk: increased risk of hip, wrist or spine fractures with long‑term use.

When prescribing Omeprazole Stada, consider the following safety measures:

• Assess renal and hepatic function: adjust use if impairment.
• Review medication history: avoid concomitant use with drugs that require acidic gastric pH for absorption.\n- Monitor for long‑term therapy: consider periodic assessment of magnesium and vitamin B12.
• Pregnancy and lactation: use only if clearly needed.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Omeprazole Stada can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Clopidogrel: decreased antiplatelet effect.
• Atazanavir: reduced absorption due to increased gastric pH.
• Ketoconazole: markedly reduced absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR.
• Phenytoin: reduced serum levels.
• Digoxin: possible increase in serum concentration.
• Methotrexate: enhanced toxicity at high doses.